Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2014 Oct 28;64(17):1789-97.
doi: 10.1016/j.jacc.2014.04.089. Epub 2014 Oct 21.

B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women

Affiliations
Observational Study

B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women

Brendan M Everett et al. J Am Coll Cardiol. .

Abstract

Background: Although N-terminal pro-B-type natriuretic peptide (NT-proBNP) has a strong relationship with incident cardiovascular disease (CVD), few studies have examined whether NT-proBNP adds to risk prediction algorithms, particularly in women.

Objectives: This study sought to evaluate the relationship between NT-proBNP and incident CVD in women.

Methods: Using a prospective case-cohort within the WHI (Women's Health Initiative) observational study, we selected 1,821 incident cases of CVD (746 myocardial infarctions, 754 ischemic strokes, 160 hemorrhagic strokes, and 161 other cardiovascular [CV] deaths) and a randomly selected reference cohort of 1,992 women without CVD at baseline.

Results: Median levels of NT-proBNP were higher at study entry among incident cases (120.3 ng/l [interquartile range (IQR): 68.1 to 219.5 ng/l]) than among control subjects (100.4 ng/l [IQR: 59.7 to 172.6 ng/l]; p < 0.0001). Women in the highest quartile of NT-proBNP (≥140.8 ng/l) were at 53% increased risk of CVD versus those in the lowest quartile after adjusting for traditional risk factors (1.53 [95% confidence interval (CI): 1.21 to 1.94]; p for trend <0.0001). Similar associations were observed after adjustment for Reynolds Risk Score covariables (1.53 [95% CI: 1.20 to 1.95]; p for trend <0.0001); the association remained in separate analyses of CV death (2.66 [95% CI: 1.48 to 4.81]; p for trend <0.0001), myocardial infarction (1.39 [95% CI: 1.02 to 1.88]; p for trend = 0.008), and stroke (1.60 [95% CI: 1.22 to 2.11]; p for trend <0.0001). When added to traditional risk covariables, NT-proBNP improved the c-statistic (0.765 to 0.774; p = 0.0003), categorical net reclassification (0.08; p < 0.0001), and integrated discrimination (0.0105; p < 0.0001). Similar results were observed when NT-proBNP was added to the Reynolds Risk Score.

Conclusions: In this multiethnic cohort of women with numerous CV events, NT-proBNP modestly improved measures of CVD risk prediction.

Keywords: biomarkers; multiethnic; prevention; risk prediction.

PubMed Disclaimer

Conflict of interest statement

Disclosures

Drs. Manson and Cook have no relevant conflicts to disclose.

Figures

FIGURE
FIGURE. Central Illustration. Improving Cardiovascular Disease (CVD) Risk Prediction in Women by Adding NT-proBNP Levels to Existing Algorithms
NT-proBNP concentrations were measured in 1821 women with incident cardiovascular disease (746 myocardial infarction, 754 ischemic stroke, 160 hemorrhagic stroke, 161 cardiovascular death) and a randomly selected reference subcohort of 1992 women without cardiovascular disease at baseline. Panel 1 depicts the distribution of NT-proBNP concentrations in the reference subcohort. Panel 2 shows the risk of the combined cardiovascular endpoint (myocardial infarction, stroke, or cardiovascular death) according to increasing quartiles of NT-proBNP. Panel 3 depicts the addition of NT-proBNP to traditional risk factors in risk prediction algorithms, which leads to modest but statistically significant improvements in the ability to predict 10-year cardiovascular disease risk.

Comment in

References

    1. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167. - PubMed
    1. Januzzi JL, Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954. - PubMed
    1. Thygesen K, Mair J, Mueller C, et al. Recommendations for the use of natriuretic peptides in acute cardiac care: a position statement from the Study Group on Biomarkers in Cardiology of the ESC Working Group on Acute Cardiac Care. Eur Heart J. 2012;33:2001–2006. - PubMed
    1. Di Angelantonio E, Chowdhury R, Sarwar N, et al. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation. 2009;120:2177–2187. - PubMed
    1. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J. 2007;28:1374–1381. - PubMed

Publication types

Substances